204
- Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, et al. Golimumab 3-year safety
update: an analysis of pooled data from the long-term extensions of randomised, double-
blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic
arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015;74:538–46. - Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, et al.
Biologic therapies and risk of infection and malignancy in patients with inflammatory
bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol.
2016;14:1385–97. - Moćko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of ulcerative
colitis: a systematic review and network meta-analysis. Pharmacotherapy. 2016;36:870–9. - Moćko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of Crohn disease:
a systematic review and network meta-analysis. Pharmacol Rep. 2016;68:1237–43. - Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel J-F. Efficacy
and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-
controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–53. - Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α
therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am
J Gastroenterol. 2013;108:1268–76. - Wang X, Zhou F, Zhao J, Zhou R, Huang M, Li J, et al. Elevated risk of opportunistic viral
infection in patients with Crohn’s disease during biological therapies: a meta analysis of
randomized controlled trials. Eur J Clin Pharmacol. 2013;69:1891–9. - Colombel J-F, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, et al. Adalimumab
safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis.
2009;15:1308–19. - Chen X, Hou J, Yuan Y, Huang C, Liu T, Mo C, et al. Adalimumab for moderately to
severely active ulcerative colitis: a systematic review and meta-analysis. BioDrugs.
2016;30:207–17. - Shao L, Chen M, Cai J. Meta-analysis: the efficacy and safety of certolizumab pegol in
Crohn’s disease. Aliment Pharmacol Ther. 2009;29:605–14. - Da W, Zhu J, Wang L, Lu Y. Efficacy and safety of certolizumab pegol for Crohn’s disease: a
systematic review and meta-analysis. Adv Ther. 2013;30:541–53. - Lichtenstein G, Feagan B, Sandborn W, Hasan I, Kosutic G, Coarse J, et al. Serious infectious
complications in patients treated with certolizumab pegol: a pooled analysis of 15 crohn’s
disease global clinical trials. Gastroenterology. 2015;148(4):S236. - Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous
golimumab induces clinical response and remission in patients with moderate-to-severe
ulcerative colitis. Gastroenterology. 2014;146:85–95. - Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous
golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Gastroenterology. 2014;146:96–109. - Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, et al. Maintenance
of efficacy and continuing safety of golimumab for active ulcerative colitis: PURSUIT-SC
maintenance study extension through 1 year. Clin Transl Gastroenterol. 2016;7:e168. - Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American gastroen-
terological association institute guideline on the use of thiopurines, methotrexate, and anti-
TNF-?? Biologic drugs for the induction and maintenance of remission in inflammatory
Crohn’s disease. Gastroenterology. 2013;145:1459–63. - FDA Drug Safety Communication: drug labels for the tumor necrosis factor-alpha (TNFα)
blockers now include warnings about infection with Legionella and Listeria bacteria. 2016.
Cited 1 July 2016. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm. - Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic
infections and malignancies during treatment with anti-integrin antibodies in inflammatory
bowel disease. Aliment Pharmacol Ther. 2015;41:1227–36.
R.M. MarchionifiBeery and J.R. Korzenik